## DTx REGULATORY & REIMBURSEMENT PATHWAYS

### GERMANY

#### Regulatory

<table>
<thead>
<tr>
<th>Category Name</th>
<th>Medical Device</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conformity Assessment</td>
<td>CE Mark granted by a designated Authorized Notified Body or self-declared by the manufacturer in the case of lower risk class devices (risk class I)</td>
</tr>
<tr>
<td>Responsible National Regulatory Agency</td>
<td>Federal Institute for Drugs and Medical Devices (BfArM)</td>
</tr>
</tbody>
</table>

#### Products that Qualify For Regulatory Review

DTx manufacturers complete a self-assessment risk classification (according to this MDCG guideline) to determine how the CE Marking is carried out.

Class I products do not qualify for regulatory review by a notified body. The manufacturer self-declares conformity to the MDR and assigns the CE label themselves. Currently, most DiGA in Germany are risk class I devices.

*Products that qualify for regulatory review include:*
  - **Class IIa:** It is anticipated that most DTx software will fall under this classification in the future. However, right now most DTx manufacturers in Germany do seek risk class I classification.
  - **Class IIb:** Includes DTx products with higher risks or consequences.
  - **Class III:** No Class III DTx products currently exist, but this is possible in the future.

#### Pre-Submission Opportunities

No process exists.

#### Guidelines To Be Met

**Key systems:**
- Company-wide quality management system (QMS) according to MDR article 10, compliant with ISO 13485 and product-specific technical documentation (MDR annex I, II and III, covering IEC 62304, IEC 62366, and ISO 14971).
- Clinical evaluation report according to MDR Article 61 (annex XIV and XV), MDCG, and MEDDEV 2.7.
- Post-market surveillance report according to MDR Article 85 for Class I and Article 86 for Class IIa, IIb, and III.

**Personnel requirements:**
- Minimum of one Person Responsible for Regulatory Compliance (PRRC).
- Manufacturers not registered in the EU must appoint an Authorized European Representative.

**Full regulation:** [MDR 2017/745](#)

#### Other Guidelines

CE Mark applies to all European countries at this time.

Significant changes (see the [MDCG 2020-3 Rev. 1 guidance document](#) for further information on the definition of significant changes) to the software may require a re-certification by the responsible authority.

GDPR (General Data Protection Regulation) compliance is required; data hostage within the EU is necessary due to a currently invalid EU-US data privacy shield.

*Note: Class I products need to fulfill the same guidelines as higher risk products, but do not need to involve a notified body in the process.*

#### Product Recognition

Notified bodies: CE Mark granted.

BfArM: DiGA (also known as Digital Health Applications or Digitale Gesundheitsanwendungen in German).

#### Approximate Timing For Process Completion

To establish conformity with the MDR (for risk class I devices): 6 months

For regulatory approval process by external NB: 12-18 months, although the timeline is currently extended due to the limited number of notified bodies.

#### Cost

Cost dependent on product and company size, as well as internal regulatory expertise and capacity.

---

Visit [www.dtxalliance.org](http://www.dtxalliance.org) to learn more.
## Reimbursement

### Prescription Required?

No, but an official diagnosis (as well as evidence that no contra-diagnosis is prevalent) is required and depends upon approval from the health insurance. Despite an alternative non-prescription path to receive DiGA, clinicians are seen as the main gatekeeper in driving adoption.

DiGA self prescribed through insurance: 11%
DiGA prescribed through doctor: 89%*

### Public Insurance Coverage

Main market for reimbursement in Germany, as statutory health insurances (SHIs) cover ~90% of the population

Two main options: DiGA and selective contracts

**DiGA:** listed on DiGA directory according to the Digital Care Act (SGB V § 33a) and 100% reimbursed by all SHIs
BfArM is the competent authority for DiGA listing.
Actual price is set by DiGA manufacturer and replaced after 12 months by the remuneration negotiated with the National Association of statutory health insurances (GKV-SV).

**Requirements:**
- General requirements: Risk Class I, Iia or Iib medical device (CE mark), compliant with Annex I and II of DiGAV on data protection and information security, interoperability, robustness, consumer protection, ease of use, support of healthcare providers, quality of medical content, and patient safety (aprx. 120 questions).
- Clinical evidence: DiGA has to prove at least one positive healthcare effect (positive Versorgungseffekte pVE) which can be a medical benefit (mN) or a patient-relevant improvement of structure and processes (pSVV).
- Clinical evidence has to be demonstrated at least in a retrospective comparative study with a very strong preference in practice for RCTs (effectively all relevant DiGA studies are RCTs).

Two paths to enter DiGA directory.
Details provided in BfArM Guide.

- Permanent listing: DiGA application fulfills all requirements and has sufficient clinical evidence.
- Preliminary listing: DiGA fulfills all general requirements and has conducted a (usually controlled) pilot study that makes it plausible that the main study will show a significant effect. After listing the manufacturer has 12 months to submit clinical evidence according to the approved evaluation concept to be listed permanently. This trial period can be prolonged 12 months, with application latest 4 months before end of first 12 months period. If claims are not met, DiGA will be removed from DiGA directory and no longer reimbursed.

### Private Health Insurance

10% of the German population is privately insured (option to switch to a private health insurance above certain salary threshold).

Private health insurances are currently not obliged to cover DiGA and no dedicated alternative path for DTx reimbursement exists. Possibility to negotiate reimbursement agreement with each private health insurance (currently 47).

### Employer-Sponsored Healthcare

Not common as of today, but can become part of corporate health management schemes.
Few examples for DTx exist already.

### Consumer-Funded

Very low willingness to pay out of pocket in healthcare.
Possibility to use D2C marketing mechanisms for DiGA or selective contracts as prescription is not always necessary.

*Numbers from SHI DIGA report 2023.
Note: This document represents pathways that continue to evolve. It does not provide legal advice.